CONSEQUENCES AND VALIDITY OF AN EMPIRICAL ESTIMATION OF THE NICE COST EFFECTIVENESS THRESHOLD

被引：0
|
作者：
Grobler, M. [1 ]
Lothgren, M. [2 ]
机构：
[1] Amgen Inc, N Ryde, NSW, Australia
[2] Amgen Europe GmbH, Zug, Switzerland
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.047
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
HT1
引用
收藏
页码：S8 / S8
页数：1
相关论文
共 50 条
  • [1] NICE's cost effectiveness threshold - How high should it be?
    Appleby, John
    Devlin, Nancy
    Parkin, David
    [J]. BRITISH MEDICAL JOURNAL, 2007, 335 (7616): : 358 - 359
  • [2] The NICE cost-effectiveness threshold - What it is and what that means
    McCabe, Christopher
    Claxton, Karl
    Culyer, Anthony J.
    [J]. PHARMACOECONOMICS, 2008, 26 (09) : 733 - 744
  • [3] NICE'S COST-EFFECTIVENESS THRESHOLD REVISITED: NEW EVIDENCE ON THE INFLUENCE OF COST-EFFECTIVENESS AND OTHER FACTORS ON NICE DECISIONS
    Devlin, N.
    Dakin, H.
    Rice, N.
    Parkin, D.
    O'Neill, P.
    [J]. VALUE IN HEALTH, 2010, 13 (07) : A246 - A246
  • [4] THRESHOLD VALUES FOR COST-EFFECTIVENESS IN AHTAPOL AND NICE FOR CANCER DRUG TECHNOLOGIES
    Kiljan, A.
    Kolasa, K.
    Hermanowski, T.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A467 - A467
  • [5] On the Estimation of the Cost-Effectiveness Threshold: Why, What, How?
    Vallejo-Torres, Laura
    Garcia-Lorenzo, Borja
    Castilla, Ivan
    Valcarcel-Nazco, Cristina
    Garcia-Perez, Lidia
    Linertova, Renata
    Polentinos-Castro, Elena
    Serrano-Aguilar, Pedro
    [J]. VALUE IN HEALTH, 2016, 19 (05) : 558 - 566
  • [6] COST-EFFECTIVENESS OF END-OF-LIFE, LIFE-EXTENDING INTERVENTIONS: NICE'S COST-EFFECTIVENESS THRESHOLD EXPLORED
    Hamerslag, L.
    Haynes, S.
    Kusel, J.
    Costello, S.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A243 - A243
  • [7] Cost-effectiveness considerations at NICE
    Rawlins, Michael
    Dillon, Andrew
    [J]. LANCET, 2008, 372 (9646): : 1302 - 1302
  • [8] The NICE Cost-Effectiveness ThresholdWhat it is and What that Means
    Christopher McCabe
    Karl Claxton
    Anthony J. Culyer
    [J]. PharmacoEconomics, 2008, 26 : 733 - 744
  • [9] Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold
    Claxton, Karl
    Martin, Steve
    Soares, Marta
    Rice, Nigel
    Spackman, Eldon
    Hinde, Sebastian
    Devlin, Nancy
    Smith, Peter C.
    Sculpher, Mark
    [J]. HEALTH TECHNOLOGY ASSESSMENT, 2015, 19 (14) : 1 - +
  • [10] Contradictions and the cost-effectiveness threshold
    Santos, Marisa da Silva
    Pinto, Marcia
    Trajman, Anete
    [J]. CADERNOS DE SAUDE PUBLICA, 2017, 33 (08):
12345